Matches in Wikidata for { <http://www.wikidata.org/entity/Q99590063> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q99590063 description "article scientifique publié en 2020" @default.
- Q99590063 description "artículu científicu espublizáu en setiembre de 2020" @default.
- Q99590063 description "scientific article published on 18 September 2020" @default.
- Q99590063 description "wetenschappelijk artikel" @default.
- Q99590063 description "наукова стаття, опублікована 18 вересня 2020" @default.
- Q99590063 name "Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation" @default.
- Q99590063 name "Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation" @default.
- Q99590063 type Item @default.
- Q99590063 label "Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation" @default.
- Q99590063 label "Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation" @default.
- Q99590063 prefLabel "Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation" @default.
- Q99590063 prefLabel "Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation" @default.
- Q99590063 P1433 Q99590063-496C7367-3236-4050-8C20-F3A4D2EADD36 @default.
- Q99590063 P1476 Q99590063-EB01963B-CC7B-4E8B-9DEB-BDB4B9225270 @default.
- Q99590063 P2093 Q99590063-06185E2E-780C-46A8-B5AE-783D6E769893 @default.
- Q99590063 P2093 Q99590063-4B702DFE-16D7-491D-BBB7-5637D0C8EFBE @default.
- Q99590063 P2093 Q99590063-6294EB08-D4D8-4D49-9E92-151B19C43233 @default.
- Q99590063 P2093 Q99590063-71D515DF-C5C5-4B7C-A22F-0583C40E71B0 @default.
- Q99590063 P2093 Q99590063-97E0229A-1FCD-4019-B216-EE6429273863 @default.
- Q99590063 P2093 Q99590063-DD510572-BD41-4F53-88EF-6DCE5E808A53 @default.
- Q99590063 P2093 Q99590063-E46169DE-1461-4276-898D-45E719DA22C8 @default.
- Q99590063 P304 Q99590063-361777F4-A92A-4430-B8AE-B6B05761E5E6 @default.
- Q99590063 P31 Q99590063-1A01EA7F-9177-477F-BE48-FC017D408C97 @default.
- Q99590063 P356 Q99590063-C5025B23-39A0-4D50-BF3B-E29FE4C9908D @default.
- Q99590063 P577 Q99590063-B9FE63CF-E146-45C8-A7A5-63B0FA6C638A @default.
- Q99590063 P698 Q99590063-6B2DE3BC-E9E6-4433-903E-57155D13D559 @default.
- Q99590063 P921 Q99590063-5F000DC5-BA1E-47D3-8811-8CAB96D0EDEE @default.
- Q99590063 P356 J.IJPHARM.2020.119895 @default.
- Q99590063 P698 32956821 @default.
- Q99590063 P1433 Q6051539 @default.
- Q99590063 P1476 "Formulation of nanoliposome-encapsulated bevacizumab (Avastin): Statistical optimization for enhanced drug encapsulation and properties evaluation" @default.
- Q99590063 P2093 "Alireza Baradaran-Rafii" @default.
- Q99590063 P2093 "Daniela Monti" @default.
- Q99590063 P2093 "Dina Morshedi" @default.
- Q99590063 P2093 "Elahe Elahi" @default.
- Q99590063 P2093 "Farhang Aliakbari" @default.
- Q99590063 P2093 "Hasan Bardania" @default.
- Q99590063 P2093 "Maryam Malakouti-Nejad" @default.
- Q99590063 P304 "119895" @default.
- Q99590063 P31 Q13442814 @default.
- Q99590063 P356 "10.1016/J.IJPHARM.2020.119895" @default.
- Q99590063 P577 "2020-09-18T00:00:00Z" @default.
- Q99590063 P698 "32956821" @default.
- Q99590063 P921 Q413299 @default.